FY2026 Earnings Forecast for YMAB Issued By HC Wainwright

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Investment analysts at HC Wainwright issued their FY2026 earnings estimates for shares of Y-mAbs Therapeutics in a report released on Monday, May 19th. HC Wainwright analyst R. Burns anticipates that the company will earn ($0.92) per share for the year. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.65) per share.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.10. The business had revenue of $20.90 million during the quarter, compared to analysts’ expectations of $19.97 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%.

Several other analysts have also commented on YMAB. Oppenheimer lowered their price objective on shares of Y-mAbs Therapeutics from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday, May 14th. Bank of America downgraded Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 target price on the stock. in a report on Tuesday, April 22nd. Truist Financial reduced their price target on Y-mAbs Therapeutics from $18.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, May 14th. Wedbush reissued an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. Finally, Morgan Stanley cut their price target on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a report on Wednesday, March 5th. Two investment analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $16.60.

Y-mAbs Therapeutics Trading Down 3.1%

Shares of NASDAQ YMAB opened at $4.10 on Tuesday. The firm has a fifty day simple moving average of $4.43 and a two-hundred day simple moving average of $6.89. Y-mAbs Therapeutics has a 12 month low of $3.55 and a 12 month high of $16.11. The firm has a market capitalization of $185.66 million, a PE ratio of -7.59 and a beta of 0.53.

Insider Transactions at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the sale, the insider now directly owns 202,721 shares of the company’s stock, valued at approximately $1,060,230.83. This represents a 5.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 22.50% of the company’s stock.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Paradigm Biocapital Advisors LP grew its holdings in Y-mAbs Therapeutics by 3.7% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company’s stock valued at $33,171,000 after purchasing an additional 150,000 shares during the period. Acorn Capital Advisors LLC increased its holdings in Y-mAbs Therapeutics by 13.1% in the 1st quarter. Acorn Capital Advisors LLC now owns 3,235,387 shares of the company’s stock worth $14,333,000 after acquiring an additional 373,562 shares in the last quarter. Caligan Partners LP raised its stake in Y-mAbs Therapeutics by 47.9% during the 4th quarter. Caligan Partners LP now owns 1,767,982 shares of the company’s stock worth $13,843,000 after acquiring an additional 572,729 shares during the period. Geode Capital Management LLC raised its stake in Y-mAbs Therapeutics by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 822,309 shares of the company’s stock worth $6,440,000 after acquiring an additional 8,820 shares during the period. Finally, Pictet Asset Management Holding SA lifted its holdings in Y-mAbs Therapeutics by 9.9% during the fourth quarter. Pictet Asset Management Holding SA now owns 756,297 shares of the company’s stock valued at $5,922,000 after purchasing an additional 68,317 shares in the last quarter. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.